![](https://www.diabetesnews.com/wp-content/uploads/2014/05/pill-78915b8cd74585c6c282cabd78b904bc4a708dd8-s6-c30-150x150.jpg)
A study found that the development of type 2 diabetes was reduced by 32% in participants who took the SGLT-2 inhibitor medication dapagliflozin instead of placebo, suggesting there may be a possible prevention, as well as treatment, role for this diabetes drug. Read more